BMS-564929

DB07286ExperimentalSmall molecule

BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.

Mechanism: Pharmacologically active on Androgen receptor
Curator reviewed
Formula / weight: C₁₄H₁₂ClN₃O₃ · 305.716 g/mol (avg)
Code names: BMS-564,929

Resolves to

Compound

UNII9BLW27W4X7CAS627530-84-1ChEMBLCHEMBL229264PubChem9882972

Structure

InChIKeyKEJORAMIZFOODM-PWSUYJOCSA-NSMILES[H][C@@]1(O)CCN2C(=O)N(C(=O)[C@]12[H])C1=C(C)C(Cl)=C(C=C1)C#N

Targets

P10275AR

What you can answer from here — as of August 26, 2024

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with BMS-564929, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account